

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

THIS PAGE BLANK (USPTO)

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 0 894 855 A2

(12)

EUROPEAN PATENT APPLICATION

(43) Date of publication:
03.02.1999 Bulletin 1999/05

(51) Int. Cl.⁶: **C12N 15/12, C07K 14/47,
C12N 5/10, C07K 16/18,
G01N 33/53, G01N 33/68**

(21) Application number: 97310566.1

(22) Date of filing: 23.12.1997

(84) Designated Contracting States:
**AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC
NL PT SE**
Designated Extension States:
AL LT LV MK RO SI

(72) Inventor:
**Chabot-Fletcher, Marie C.,
SmithKline Beecham Pha.
King of Prussia, Pennsylvania 19406 (US)**

(30) Priority: 31.07.1997 US 903851

(74) Representative:
**Crump, Julian Richard John et al
FJ Cleveland,
40-43 Chancery Lane
London WC2A 1JQ (GB)**

(71) Applicant:
**SMITHKLINE BEECHAM CORPORATION
Philadelphia Pennsylvania 19103 (US)**

(54) Human I kappa B-beta transcription factor

(57) I κ B- β polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing I κ B- β polypeptides and polynucleotides in the design of protocols for the treatment of inflammatory conditions including but not limited to rheumatoid arthritis, dermatosis (eg. psoriasis), inflammatory bowel disease, autoimmune diseases, tissue and/or organ rejection, Alzheimer's disease, stroke, atherosclerosis, restenosis, cancer, viral infection including but not limited to AIDS, osteoarthritis, osteoporosis, and Ataxia Telangiectasia, among others, and diagnostic assays for such conditions.

EP 0 894 855 A2

Description

FIELD OF INVENTION

- 5 [0001] This invention relates to newly identified polynucleotides, polypeptides encoded by them and to the use of such polynucleotides and polypeptides, and to their production. More particularly, the polynucleotides and polypeptides of the present invention relate to the I κ B family, hereinafter referred to as I κ B- β . The invention also relates to inhibiting or activating the action of such polynucleotides and polypeptides.

10 BACKGROUND OF THE INVENTION

The transcription factor NF- κ B is key in regulating the expression of many genes involved in immune and inflammatory processes. In most cells NF- κ B is present in the cytoplasm complexed with a member of the I κ B family of proteins. I κ B was originally identified as a labile factor which inhibited the activity of NF- κ B by a directed protein-protein interaction. 15 Two forms of the protein I κ B- α and I κ B- β , were purified from cytosolic fractions of human placenta (Zabel and Baeuerle, Cell 61:255-265, 1990) and at least three additional I κ B family members have been described (Miyamoto and Verma, Adv. Cancer Res. 66:255-292, 1995). The activation of NF- κ B upon cell activation is thought to involve the inducible phosphorylation of I κ B family members on two N-terminal serines by a novel kinase prior to its degradation thereby allowing the free NF- κ B to migrate to the nucleus where it binds to its consensus motif in target genes. Inhibition of 20 either I κ B phosphorylation or its degradation is known to inhibit the activation of NF- κ B and thereby inhibit the expression of a number of immune and inflammatory mediators. This indicates that the I κ B family has an established, proven history as therapeutic targets. Clearly there is a need for identification and characterization of further members of the I κ B family which can play a role in preventing, ameliorating or correcting dysfunctions or diseases, including, but not limited to, inflammatory conditions including but not limited to rheumatoid arthritis, dermatosis (eg. psoriasis), inflammatory 25 bowel disease, autoimmune diseases, tissue and/or organ rejection, Alzheimer's disease, stroke, atherosclerosis, restenosis, cancer, viral infection including but not limited to AIDS, osteoarthritis, osteoporosis, and Ataxia Telangiectasia.

SUMMARY OF THE INVENTION

30 [0002] In one aspect, the invention relates to I κ B- β polypeptides and recombinant materials and methods for their production. Another aspect of the invention relates to methods for using such I κ B- β polypeptides and polynucleotides. Such uses include the treatment of inflammatory conditions including but not limited to rheumatoid arthritis, dermatosis (eg. psoriasis), inflammatory bowel disease, autoimmune diseases, tissue and/or organ rejection, Alzheimer's disease, 35 stroke, atherosclerosis, restenosis, cancer, viral infection including but not limited to AIDS, osteoarthritis, osteoporosis, and Ataxia Telangiectasia, among others. In still another aspect, the invention relates to methods to identify agonists and antagonists using the materials provided by the invention, and treating conditions associated with I κ B- β imbalance with the identified compounds. Yet another aspect of the invention relates to diagnostic assays for detecting diseases associated with inappropriate I κ B- β activity or levels.

40 DESCRIPTION OF THE INVENTION

Definitions

- 45 [0003] The following definitions are provided to facilitate understanding of certain terms used frequently herein.
 [0004] "I κ B- β " refers, among others, generally to a polypeptide having the amino acid sequence set forth in SEQ ID NO:2 or an allelic variant thereof.
 [0005] "I κ B- β activity or I κ B- β polypeptide activity" or "biological activity of the I κ B- β or I κ B- β polypeptide" refers to the metabolic or physiologic function of said I κ B- β including similar activities or improved activities or these activities 50 with decreased undesirable side-effects. Also included are antigenic and immunogenic activities of said I κ B- β .
 [0006] "I κ B- β gene" refers to a polynucleotide having the nucleotide sequence set forth in SEQ ID NO:1 or allelic variants thereof and/or their complements.
 [0007] "Antibodies" as used herein includes polyclonal and monoclonal antibodies, chimeric, single chain, and humanized antibodies, as well as Fab fragments, including the products of an Fab or other immunoglobulin expression 55 library.
 [0008] "Isolated" means altered "by the hand of man" from the natural state. If an "isolated" composition or substance occurs in nature, it has been changed or removed from its original environment, or both. For example, a polynucleotide or a polypeptide naturally present in a living animal is not "isolated," but the same polynucleotide or polypeptide sepa-

rated from the coexisting materials of its natural state is "isolated", as the term is employed herein.

[0009] "Polynucleotide" generally refers to any polyribonucleotide or polydeoxiribonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA. "Polynucleotides" include, without limitation single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions, single- and double-stranded RNA, and RNA that is mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded or a mixture of single- and double-stranded regions. In addition, "polynucleotide" refers to triple-stranded regions comprising RNA or DNA or both RNA and DNA. The term polynucleotide also includes DNAs or RNAs containing one or more modified bases and DNAs or RNAs with backbones modified for stability or for other reasons. "Modified" bases include, for example, tritylated bases and unusual bases such as inosine. A variety of modifications has been made to DNA and RNA; thus, "polynucleotide" embraces chemically, enzymatically or metabolically modified forms of polynucleotides as typically found in nature, as well as the chemical forms of DNA and RNA characteristic of viruses and cells. "Polynucleotide" also embraces relatively short polynucleotides, often referred to as oligonucleotides.

[0010] "Polypeptide" refers to any peptide or protein comprising two or more amino acids joined to each other by peptide bonds or modified peptide bonds, i.e., peptide isosteres. "Polypeptide" refers to both short chains, commonly referred to as peptides, oligopeptides or oligomers, and to longer chains, generally referred to as proteins. Polypeptides may contain amino acids other than the 20 gene-encoded amino acids. "Polypeptides" include amino acid sequences modified either by natural processes, such as posttranslational processing, or by chemical modification techniques which are well known in the art. Such modifications are well described in basic texts and in more detailed monographs, as well as in a voluminous research literature. Modifications can occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini. It will be appreciated that the same type of modification may be present in the same or varying degrees at several sites in a given polypeptide. Also, a given polypeptide may contain many types of modifications. Polypeptides may be branched as a result of ubiquitination, and they may be cyclic, with or without branching. Cyclic, branched and branched cyclic polypeptides may result from post-translation natural processes or may be made by synthetic methods. Modifications include acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphotidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cystine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination. See, for instance, PROTEINS - STRUCTURE AND MOLECULAR PROPERTIES, 2nd Ed., T. E. Creighton, W. H. Freeman and Company, New York, 1993 and Wold, F., Posttranslational Protein Modifications: Perspectives and Prospects, pgs. 1-12 in POSTTRANSLATIONAL COVALENT MODIFICATION OF PROTEINS, B. C. Johnson, Ed., Academic Press, New York, 1983; Seifter *et al.*, "Analysis for protein modifications and nonprotein cofactors", *Meth Enzymol* (1990) 182:626-646 and Rattan *et al.*, "Protein Synthesis: Posttranslational Modifications and Aging", *Ann NY Acad Sci* (1992) 663:48-62.

[0011] "Variant" as the term is used herein, is a polynucleotide or polypeptide that differs from a reference polynucleotide or polypeptide respectively, but retains essential properties. A typical variant of a polynucleotide differs in nucleotide sequence from another, reference polynucleotide. Changes in the nucleotide sequence of the variant may or may not alter the amino acid sequence of a polypeptide encoded by the reference polynucleotide. Nucleotide changes may result in amino acid substitutions, additions, deletions, fusions and truncations in the polypeptide encoded by the reference sequence, as discussed below. A typical variant of a polypeptide differs in amino acid sequence from another, reference polypeptide. Generally, differences are limited so that the sequences of the reference polypeptide and the variant are closely similar overall and, in many regions, identical. A variant and reference polypeptide may differ in amino acid sequence by one or more substitutions, additions, deletions in any combination. A substituted or inserted amino acid residue may or may not be one encoded by the genetic code. A variant of a polynucleotide or polypeptide may be a naturally occurring such as an allelic variant, or it may be a variant that is not known to occur naturally. Non-naturally occurring variants of polynucleotides and polypeptides may be made by mutagenesis techniques or by direct synthesis.

[0012] "Identity" is a measure of the identity of nucleotide sequences or amino acid sequences. In general, the sequences are aligned so that the highest order match is obtained. "Identity" *per se* has an art-recognized meaning and can be calculated using published techniques. See, e.g.: (COMPUTATIONAL MOLECULAR BIOLOGY, Lesk, A.M., ed., Oxford University Press, New York, 1988; BIOCOMPUTING: INFORMATICS AND GENOME PROJECTS, Smith, D.W., ed., Academic Press, New York, 1993; COMPUTER ANALYSIS OF SEQUENCE DATA, PART I, Griffin, A.M., and Griffin, H.G., eds., Humana Press, New Jersey, 1994; SEQUENCE ANALYSIS IN MOLECULAR BIOLOGY, von Heinje, G., Academic Press, 1987; and SEQUENCE ANALYSIS PRIMER, Gribskov, M. and Devereux, J., eds., M Stockton Press, New York, 1991). While there exist a number of methods to measure identity between two polynucleotide or polypeptide

sequences, the term "identity" is well known to skilled artisans (Carrillo, H., and Lipton, D., *SIAM J Applied Math* (1988) 48:1073). Methods commonly employed to determine identity or similarity between two sequences include, but are not limited to, those disclosed in Guide to Huge Computers, Martin J. Bishop, ed., Academic Press, San Diego, 1994, and Carrillo, H., and Lipton, D., *SIAM J Applied Math* (1988) 48:1073. Methods to determine identity and similarity are codified in computer programs. Preferred computer program methods to determine identity and similarity between two sequences include, but are not limited to, GCS program package (Devereux, J., et al., *Nucleic Acids Research* (1984) 12(1):387), BLASTP, BLASTN, FASTA (Atschul, S.F. et al., *J Molec Biol* (1990) 215:403).

[0013] As an illustration, by a polynucleotide having a nucleotide sequence having at least, for example, 95% "identity" to a reference nucleotide sequence of SEQ ID NO: 1 is intended that the nucleotide sequence of the polynucleotide is identical to the reference sequence except that the polynucleotide sequence may include up to five point mutations per each 100 nucleotides of the reference nucleotide sequence of SEQ ID NO: 1. In other words, to obtain a polynucleotide having a nucleotide sequence at least 95% identical to a reference nucleotide sequence, up to 5% of the nucleotides in the reference sequence may be deleted or substituted with another nucleotide, or a number of nucleotides up to 5% of the total nucleotides in the reference sequence may be inserted into the reference sequence. These mutations of the reference sequence may occur at the 5 or 3 terminal positions of the reference nucleotide sequence or anywhere between those terminal positions, interspersed either individually among nucleotides in the reference sequence or in one or more contiguous groups within the reference sequence.

[0014] Similarly, by a polypeptide having an amino acid sequence having at least, for example, 95% "identity" to a reference amino acid sequence of SEQ ID NO:2 is intended that the amino acid sequence of the polypeptide is identical to the reference sequence except that the polypeptide sequence may include up to five amino acid alterations per each 100 amino acids of the reference amino acid of SEQ ID NO: 2. In other words, to obtain a polypeptide having an amino acid sequence at least 95% identical to a reference amino acid sequence, up to 5% of the amino acid residues in the reference sequence may be deleted or substituted with another amino acid, or a number of amino acids up to 5% of the total amino acid residues in the reference sequence may be inserted into the reference sequence. These alterations of the reference sequence may occur at the amino or carboxy terminal positions of the reference amino acid sequence or anywhere between those terminal positions, interspersed either individually among residues in the reference sequence or in one or more contiguous groups within the reference sequence.

Polypeptides of the Invention

[0015] In one aspect, the present invention relates to I κ B- β polypeptides (or I κ B- β proteins). The I κ B- β polypeptides include the polypeptide of SEQ ID NO:2; as well as polypeptides comprising the amino acid sequence of SEQ ID NO: 2; and polypeptides comprising the amino acid sequence which have at least 80% identity to that of SEQ ID NO:2 over its entire length, and still more preferably at least 90% identity, and even still more preferably at least 95% identity to SEQ ID NO: 2. Furthermore, those with at least 97-99% are highly preferred. Also included within I κ B- β polypeptides are polypeptides having the amino acid sequence which have at least 80% identity to the polypeptide having the amino acid sequence of SEQ ID NO:2 over its entire length, and still more preferably at least 90% identity, and still more preferably at least 95% identity to SEQ ID NO:2. Furthermore, those with at least 97-99% are highly preferred. Preferably I κ B- β polypeptide exhibit at least one biological activity of I κ B- β .

[0016] The I κ B- β polypeptides may be in the form of the "mature" protein or may be a part of a larger protein such as a fusion protein. It is often advantageous to include an additional amino acid sequence which contains secretory or leader sequences, pro-sequences, sequences which aid in purification such as multiple histidine residues, or an additional sequence for stability during recombinant production.

[0017] Fragments of the I κ B- β polypeptides are also included in the invention. A fragment is a polypeptide having an amino acid sequence that entirely is the same as part, but not all, of the amino acid sequence of the aforementioned I κ B- β polypeptides. As with I κ B- β polypeptides, fragments may be "free-standing," or comprised within a larger polypeptide of which they form a part or region, most preferably as a single continuous region. Representative examples of polypeptide fragments of the invention, include, for example, fragments from about amino acid number 1-20, 21-40, 41-60, 61-80, 81-100, and 101 to the end of I κ B- β polypeptide. In this context "about" includes the particularly recited ranges larger or smaller by several, 5, 4, 3, 2 or 1 amino acid at either extreme or at both extremes.

[0018] Preferred fragments include, for example, truncation polypeptides having the amino acid sequence of I κ B- β polypeptides, except for deletion of a continuous series of residues that includes the amino terminus, or a continuous series of residues that includes the carboxyl terminus or deletion of two continuous series of residues, one including the amino terminus and one including the carboxyl terminus. Also preferred are fragments characterized by structural or functional attributes such as fragments that comprise alpha-helix and alpha-helix forming regions, beta-sheet and beta-sheet-forming regions, turn and turn-forming regions, coil and coil-forming regions, hydrophilic regions, hydrophobic regions, alpha amphipathic regions, beta amphipathic regions, flexible regions, surface-forming regions, substrate binding region, and high antigenic index regions. Other preferred fragments are biologically active fragments. Biologically

active fragments are those that mediate I κ B- β activity, including those with a similar activity or an improved activity, or with a decreased undesirable activity. Also included are those that are antigenic or immunogenic in an animal, especially in a human.

[0019] Preferably, all of these polypeptide fragments retain the biological activity of the I κ B- β , including antigenic activity. Variants of the defined sequence and fragments also form part of the present invention. Preferred variants are those that vary from the referents by conservative amino acid substitutions -- i.e., those that substitute a residue with another of like characteristics. Typical such substitutions are among Ala, Val, Leu and Ile; among Ser and Thr; among the acidic residues Asp and Glu; among Asn and Gln; and among the basic residues Lys and Arg; or aromatic residues Phe and Tyr. Particularly preferred are variants in which several, 5-10, 1-5, or 1-2 amino acids are substituted, deleted, or added in any combination.

[0020] The I κ B- β polypeptides of the invention can be prepared in any suitable manner. Such polypeptides include isolated naturally occurring polypeptides, recombinantly produced polypeptides, synthetically produced polypeptides, or polypeptides produced by a combination of these methods. Means for preparing such polypeptides are well understood in the art.

Polynucleotides of the Invention

[0021] Another aspect of the invention relates to I κ B- β polynucleotides. I κ B- β polynucleotides include isolated polynucleotides which encode the I κ B- β polypeptides and fragments, and polynucleotides closely related thereto. More specifically, I κ B- β polynucleotide of the invention include a polynucleotide comprising the nucleotide sequence contained in SEQ ID NO:1 encoding a I κ B- β polypeptide of SEQ ID NO: 2, and polynucleotide having the particular sequence of SEQ ID NO:1. I κ B- β polynucleotides further include a polynucleotide comprising a nucleotide sequence that has at least 80% identity over its entire length to a nucleotide sequence encoding the I κ B- β polypeptide of SEQ ID NO:2, and a polynucleotide comprising a nucleotide sequence that is at least 80% identical to of SEQ ID NO:1 over its entire length. In this regard, polynucleotides at least 90% identical are particularly preferred, and those with at least 95% are especially preferred. Furthermore, those with at least 97% are highly preferred and those with at least 98-99% are most highly preferred, with at least 99% being the most preferred. Also included under I κ B- β polynucleotides are a nucleotide sequence which has sufficient identity to a nucleotide sequence contained in SEQ ID NO:1 to hybridize under conditions useable for amplification or for use as a probe or marker. The invention also provides polynucleotides which are complementary to such I κ B- β polynucleotides.

[0022] I κ B- β of the invention is structurally related to other proteins of the I κ B family, as shown by the results of sequencing the cDNA of Table 1 (SEQ ID NO:1) encoding human I κ B- β . The cDNA sequence of SEQ ID NO:1 contains an open reading frame (nucleotide number 70 to 1140) encoding a polypeptide of 357 amino acids of SEQ ID NO:2. The amino acid sequence of Table 2 (SEQ ID NO:2) has about 96.15% identity (using GAP) in 357 amino acid residues with Trip9 (J.W. Lee et al., Mol. Endocrinol. 9:243-254, 1995). Furthermore, I κ B- β (SEQ ID NO:2) is 84.3% identical to the murine I κ B- β over 360 amino acid residues (Thompson et al., Cell 80:573-582, 1995). The nucleotide sequence of Table 1 (SEQ ID NO:1) has about 88.8% identity (using GAP) over 1227 nucleotide residues with Homo sapiens thyroid receptor interacting protein-9 (J.W. Lee et al., Mol. Endocrinol. 9:243-254, 1995). Furthermore, I κ B- β (SEQ ID NO:1) is 80.2% identical to murine I κ B- β over 1242 nucleotide base residues (Thompson J.E. et al., Cell 80:573-582, 1995) Thus I κ B- β polypeptides and polynucleotides of the present invention are expected to have, inter alia, similar biological functions/properties to their homologous polypeptides and polynucleotides, and their utility is obvious to anyone skilled in the art.

Table 1^a

5 CGGGT CGACCCACGCGT CCGCCCAGCT ACAGGCGGGCGACTGCGGGGGGCCCCTGAGGCGGCGGGGGCC
 ATGGCTGGGGT CGCGT GCTTGGGAAAAGCTGCGACG CAGATGAATGGT GCGACAGCGGCCTGGGCTCC
 CTGGGT CCGGACG CAGCGGCCCCCGGAGGACCTGGGTGGGCGCGGAGTTGGGCCCGGGGCTGTCTGG
 10 GCTCCCCTCGTCTTCGGCTACGTCACTGAGGATGGGGACACGGCACTGCACTTGGCTGTGATT CATCAG
 CATGAACCCCTTCTTGGATTTTCTTCTAGGCTTCTCGGCCGCACTGAGTACATGGACCTGCAGAATGAC
 CTAGGCCAGACAGCCCTGCACCTGGCAGCCATCCTGGGGGAGACATCCAOGGTGGAGAAGCTGTACGCA
 GCAGGCGCGGGCTGTGTGTGGCGGAGCGTAGGGGCCACACGGCGCTGCACCTGGCCTGCCGTGTGGGG
 15 GCACACGCGCTGTGCCGTGCCCTGCTT CAGCCCGCCCCGGCGCCCCAGGGAAGCCCCGACACCTAC
 CTGCTCAGGGCCCTGACCGTACTCCGACACCAACCATACCCCTGTGCTTGTACCCCGATTCCGAC
 TTGGAGAAGGAAGAAGAGGAGAGTGAGGAGGACTGGAAGCTGCAGCTGGAGGCTGAAAACCTACGAGGGC
 CACACCCCACTCCAGTGGCGTTATCCACAAAGATGTGGAGATGGTCCGGCTGCTCGAGATGCTGGA
 20 GCTGACCTTGACAAACCGGAGCCCACTGCGGCCGGAGCCCCCTTCATTTGGCAGTGGAGGCCAGGCA
 GCGGATGTGCTGGAGCTTCTCCTGAGGGCAGGCGGAACCCCTGCTGCCGCTGTACGGTGGCGCACC
 CCACTCGGCAGTGCCTGCTCGGCCCAACCCATCCTCGCCGCTCCTCGTG CACACGGAGCCCCT
 25 GAGCCCGAGGGCGAGGACGAGAAATCGGCCCTG CAGCAGCAGTAGCGACAGCGACAGCGGAGACGAG

30 GCGATGAATACGACGACATTGTGGTT CACAGCAGCGCAGCCAAACCGGCTGCCTCCCACCCAGCC
 TCAAAACCTCTTCTGACGACCCCGCCCGTGTGATTTGTTTCATTGTTAATATAATTTCCAGTTTAA
 35 TAAACAAAACCTAGTTCTGACAACAGGAAAAAAAAAAAAAAAAAAAAAAAAA

^a A nucleotide sequence of a human IκB-β (SEQ ID NO: 1).

Table 2^b

40 MAGVACLGKAADAEWCD SGLG SLGPDAAAPGGPGLGAELGPGLSWAPLVFGYVTEDGDTALHLAVIHQ
 HEPFLDFLLGF SAGTEYMDLQNDLGQ TALHLAAILGETSTVEKLYAAGAGLCVAE RRGHTALHLACRVG
 45 AHACARALLQP RPRP REAPDTYLAQGPDRTPDNTHTPVALYPDSDLEKEEEESEEDWKLQLEAENYEG
 HTP LHVAVIHKDVEMVRLLRAGADLDKPEPTGSRPLHLAVEQAADVLELLL RAGANPAA RMYGGRT
 PLGSAML RPNPILARLL RAHGAPEPEGEDEKSGP CSSSSDSDSGDEGDEYDDIVVHSSRSQTRLPPTPA
 50 SKPLPDDP RPV.

^b An amino acid sequence of a human IκB-β (SEQ ID NO: 2).

55 [0023] One polynucleotide of the present invention encoding IκB-β may be obtained using standard cloning and screening, from a cDNA library derived from mRNA in cells of human hippocampus, synovial sarcoma, T lymphocytes, neutrophils, and pancreatic islet using the expressed sequence tag (EST) analysis (Adams, M.D., *et al. Science* (1991)

252:1651-1656; Adams, M.D. *et al.*, *Nature*, (1992) 355:632-634; Adams, M.D., *et al.*, *Nature* (1995) 377 Supp:3-174). Polynucleotides of the invention can also be obtained from natural sources such as genomic DNA libraries or can be synthesized using well known and commercially available techniques.

[0024] The nucleotide sequence encoding I κ B- β polypeptide of SEQ ID NO:2 may be identical to the polypeptide encoding sequence contained in Table 1 (nucleotide number 70 to 1140 of SEQ ID NO:1), or it may be a sequence, which as a result of the redundancy (degeneracy) of the genetic code, also encodes the polypeptide of SEQ ID NO:2.

[0025] When the polynucleotides of the invention are used for the recombinant production of I κ B- β polypeptide, the polynucleotide may include the coding sequence for the mature polypeptide or a fragment thereof, by itself; the coding sequence for the mature polypeptide or fragment in reading frame with other coding sequences, such as those encoding a leader or secretory sequence, a pre-, or pro- or prepro- protein sequence, or other fusion peptide portions. For example, a marker sequence which facilitates purification of the fused polypeptide can be encoded. In certain preferred embodiments of this aspect of the invention, the marker sequence is a hexahistidine peptide, as provided in the pQE vector (Qiagen, Inc.) and described in Gentz *et al.*, *Proc Natl Acad Sci USA* (1989) 86:821-824, or is an HA tag. The polynucleotide may also contain non-coding 5' and 3' sequences, such as transcribed, non-translated sequences, splicing and polyadenylation signals, ribosome binding sites and sequences that stabilize mRNA.

[0026] Further preferred embodiments are polynucleotides encoding I κ B- β variants comprise the amino acid sequence I κ B- β polypeptide of Table 2 (SEQ ID NO:2) in which several, 5-10, 1-5, 1-3, 1-2 or 1 amino acid residues are substituted, deleted or added, in any combination.

[0027] The present invention further relates to polynucleotides that hybridize to the herein above-described sequences. In this regard, the present invention especially relates to polynucleotides which hybridize under stringent conditions to the herein above-described polynucleotides. As herein used, the term "stringent conditions" means hybridization will occur only if there is at least 80%, and preferably at least 90%, and more preferably at least 95%, yet even more preferably 97-99% identity between the sequences.

[0028] Polynucleotides of the invention, which are identical or sufficiently identical to a nucleotide sequence contained in SEQ ID NO:1 or a fragment thereof, may be used as hybridization probes for cDNA and genomic DNA, to isolate full-length cDNAs and genomic clones encoding I κ B- β polypeptide and to isolate cDNA and genomic clones of other genes (including genes encoding homologs and orthologs from species other than human) that have a high sequence similarity to the I κ B- β gene. Such hybridization techniques are known to those of skill in the art. Typically these nucleotide sequences are 80% identical, preferably 90% identical, more preferably 95% identical to that of the referent. The probes generally will comprise at least 15 nucleotides. Preferably, such probes will have at least 30 nucleotides and may have at least 50 nucleotides. Particularly preferred probes will range between 30 and 50 nucleotides.

[0029] In one embodiment, to obtain a polynucleotide encoding I κ B- β polypeptide, including homologs and orthologs from species other than human, comprises the steps of screening an appropriate library under stringent hybridization conditions with a labeled probe having the SEQ ID NO: 1 or a fragment thereof; and isolating full-length cDNA and genomic clones containing said polynucleotide sequence. Thus in another aspect, I κ B- β polynucleotides of the present invention further include a nucleotide sequence comprising a nucleotide sequence that hybridize under stringent condition to a nucleotide sequence having SEQ ID NO: 1 or a fragment thereof. Also included with I κ B- β polypeptides are polypeptide comprising amino acid sequence encoded by nucleotide sequence obtained by the above hybridization condition. Such hybridization techniques are well known to those of skill in the art. Stringent hybridization conditions are as defined above or, alternatively, conditions under overnight incubation at 42°C in a solution comprising: 50% formamide, 5xSSC (150mM NaCl, 15mM trisodium citrate), 50 mM sodium phosphate (pH7.6), 5x Denhardt's solution, 10 % dextran sulfate, and 20 microgram/ml denatured, sheared salmon sperm DNA, followed by washing the filters in 0.1x SSC at about 65°C.

[0030] The polynucleotides and polypeptides of the present invention may be employed as research reagents and materials for discovery of treatments and diagnostics to animal and human disease.

Vectors, Host Cells, Expression

[0031] The present invention also relates to vectors which comprise a polynucleotide or polynucleotides of the present invention, and host cells which are genetically engineered with vectors of the invention and to the production of polypeptides of the invention by recombinant techniques. Cell-free translation systems can also be employed to produce such proteins using RNAs derived from the DNA constructs of the present invention.

[0032] For recombinant production, host cells can be genetically engineered to incorporate expression systems or portions thereof for polynucleotides of the present invention. Introduction of polynucleotides into host cells can be effected by methods described in many standard laboratory manuals, such as Davis *et al.*, *BASIC METHODS IN MOLECULAR BIOLOGY* (1986) and Sambrook *et al.*, *MOLECULAR CLONING: A LABORATORY MANUAL*, 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989) such as calcium phosphate transfection, DEAE-dextran mediated transfection, transfection, microinjection, cationic lipid-mediated transfection, electroporation, trans-

duction, scrape loading, ballistic introduction or infection.

[0033] Representative examples of appropriate hosts include bacterial cells, such as streptococci, staphylococci, *E. coli*, *Streptomyces* and *Bacillus subtilis* cells; fungal cells, such as yeast cells and *Aspergillus* cells; insect cells such as *Drosophila* S2 and *Spodoptera* Sf9 cells; animal cells such as CHO, COS, HeLa, C127, 3T3, BHK, HEX 293 and Bowes melanoma cells; and plant cells.

[0034] A great variety of expression systems can be used. Such systems include, among others, chromosomal, episomal and virus-derived systems, e.g., vectors derived from bacterial plasmids, from bacteriophage, from transposons, from yeast episomes, from insertion elements, from yeast chromosomal elements, from viruses such as baculoviruses, papova viruses, such as SV40, vaccinia viruses, adenoviruses, fowl pox viruses, pseudorabies viruses and retroviruses, and vectors derived from combinations thereof, such as those derived from plasmid and bacteriophage genetic elements, such as cosmids and phagemids. The expression systems may contain control regions that regulate as well as engender expression. Generally, any system or vector suitable to maintain, propagate or express polynucleotides to produce a polypeptide in a host may be used. The appropriate nucleotide sequence may be inserted into an expression system by any of a variety of well-known and routine techniques, such as, for example, those set forth in Sambrook *et al.*, *MOLECULAR CLONING, A LABORATORY MANUAL* (*supra*).

[0035] For secretion of the translated protein into the lumen of the endoplasmic reticulum, into the periplasmic space or into the extracellular environment, appropriate secretion signals may be incorporated into the desired polypeptide. These signals may be endogenous to the polypeptide or they may be heterologous signals.

[0036] If the $\text{I}\kappa\text{B}-\beta$ polypeptide is to be expressed for use in screening assays, generally, it is preferred that the polypeptide be produced at the surface of the cell. In this event, the cells may be harvested prior to use in the screening assay. If $\text{I}\kappa\text{B}-\beta$ polypeptide is secreted into the medium, the medium can be recovered in order to recover and purify the polypeptide; if produced intracellularly, the cells must first be lysed before the polypeptide is recovered. $\text{I}\kappa\text{B}-\beta$ polypeptides can be recovered and purified from recombinant cell cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. Most preferably, high performance liquid chromatography is employed for purification. Well known techniques for refolding proteins may be employed to regenerate active conformation when the polypeptide is denatured during isolation and or purification.

30 Diagnostic Assays

[0037] This invention also relates to the use of $\text{I}\kappa\text{B}-\beta$ polynucleotides for use as diagnostic reagents. Detection of a mutated form of $\text{I}\kappa\text{B}-\beta$ gene associated with a dysfunction will provide a diagnostic tool that can add to or define a diagnosis of a disease or susceptibility to a disease which results from under-expression, over-expression or altered expression of $\text{I}\kappa\text{B}-\beta$. Individuals carrying mutations in the $\text{I}\kappa\text{B}-\beta$ gene may be detected at the DNA level by a variety of techniques.

[0038] Nucleic acids for diagnosis may be obtained from a subject's cells, such as from blood, urine, saliva, tissue biopsy or autopsy material. The genomic DNA may be used directly for detection or may be amplified enzymatically by using PCR or other amplification techniques prior to analysis. RNA or cDNA may also be used in similar fashion. Deletions and insertions can be detected by a change in size of the amplified product in comparison to the normal genotype. Point mutations can be identified by hybridizing amplified DNA to labeled $\text{I}\kappa\text{B}-\beta$ nucleotide sequences. Perfectly matched sequences can be distinguished from mismatched duplexes by RNase digestion or by differences in melting temperatures. DNA sequence differences may also be detected by alterations in electrophoretic mobility of DNA fragments in gels, with or without denaturing agents, or by direct DNA sequencing. See, e.g., Myers *et al.*, *Science* (1985) 230:1242. Sequence changes at specific locations may also be revealed by nuclease protection assays, such as RNase and S1 protection or the chemical cleavage method. See Cotton *et al.*, *Proc Natl Acad Sci USA* (1985) 85: 4397-4401. In another embodiment, an array of oligonucleotide probes comprising $\text{I}\kappa\text{B}-\beta$ nucleotide sequence or fragments thereof can be constructed to conduct efficient screening of e.g., genetic mutations. Array technology methods are well known and have general applicability and can be used to address a variety of questions in molecular genetics including gene expression, genetic linkage, and genetic variability. (See for example: M.Chee *et al.*, *Science*, Vol 274, pp 610-613 (1996)).

[0039] The diagnostic assays offer a process for diagnosing or determining a susceptibility to inflammatory conditions including but not limited to rheumatoid arthritis, dermatosis (eg. psoriasis), inflammatory bowel disease, autoimmune diseases, tissue and/or organ rejection, Alzheimer's disease, stroke, atherosclerosis, restenosis, cancer, viral infection including but not limited to AIDS, osteoarthritis, osteoporosis, and Ataxia Telangiectasia through detection of mutation in the $\text{I}\kappa\text{B}-\beta$ gene by the methods described.

[0040] In addition, inflammatory conditions including but not limited to rheumatoid arthritis, dermatosis (eg. psoriasis), inflammatory bowel disease, autoimmune diseases, tissue and/or organ rejection, Alzheimer's disease, stroke, athero-

sclerosis, restenosis, cancer, viral infection including but not limited to AIDS, osteoarthritis, osteoporosis, and Ataxia Telangiectasia, can be diagnosed by methods comprising determining from a sample derived from a subject an abnormally decreased or increased level of I κ B- β polypeptide or I κ B- β mRNA. Decreased or increased expression can be measured at the RNA level using any of the methods well known in the art for the quantitation of polynucleotides, such as, for example, PCR, RT-PCR, RNase protection, Northern blotting and other hybridization methods. Assay techniques that can be used to determine levels of a protein, such as an I κ B- β polypeptide, in a sample derived from a host are well-known to those of skill in the art. Such assay methods include radioimmunoassays, competitive-binding assays, Western Blot analysis and ELISA assays.

[0041] Thus in another aspect, the present invention relates to a diagnostic kit for a disease or susceptibility to a disease, particularly inflammatory conditions including but not limited to rheumatoid arthritis, dermatosis (eg. psoriasis), inflammatory bowel disease, autoimmune diseases, tissue and/or organ rejection, Alzheimer's disease, stroke, atherosclerosis, restenosis, cancer, viral infection including but not limited to AIDS, osteoarthritis, osteoporosis, and Ataxia Telangiectasia, which comprises:

- (a) a I κ B- β polynucleotide, preferably the nucleotide sequence of SEQ ID NO: 1, or a fragment thereof;
- (b) a nucleotide sequence complementary to that of (a);
- (c) a I κ B- β polypeptide, preferably the polypeptide of SEQ ID NO: 2, or a fragment thereof; or
- (d) an antibody to a I κ B- β polypeptide, preferably to the polypeptide of SEQ ID NO: 2.

It will be appreciated that in any such kit, (a), (b), (c) or (d) may comprise a substantial component.

Chromosome Assays

[0042] The nucleotide sequences of the present invention are also valuable for chromosome identification. The sequence is specifically targeted to and can hybridize with a particular location on an individual human chromosome. The mapping of relevant sequences to chromosomes according to the present invention is an important first step in correlating those sequences with gene associated disease. Once a sequence has been mapped to a precise chromosomal location, the physical position of the sequence on the chromosome can be correlated with genetic map data. Such data are found, for example, in V. McKusick, Mendelian Inheritance in Man (available on line through Johns Hopkins University Welch Medical Library). The relationship between genes and diseases that have been mapped to the same chromosomal region are then identified through linkage analysis (coinheritance of physically adjacent genes).

[0043] The differences in the cDNA or genomic sequence between affected and unaffected individuals can also be determined. If a mutation is observed in some or all of the affected individuals but not in any normal individuals, then the mutation is likely to be the causative agent of the disease.

Antibodies

[0044] The polypeptides of the invention or their fragments or analogs thereof, or cells expressing them can also be used as immunogens to produce antibodies immunospecific for the I κ B- β polypeptides. The term "immunospecific" means that the antibodies have substantially greater affinity for the polypeptides of the invention than their affinity for other related polypeptides in the prior art.

[0045] Antibodies generated against the I κ B- β polypeptides can be obtained by administering the polypeptides or epitope-bearing fragments, analogs or cells to an animal, preferably a nonhuman, using routine protocols. For preparation of monoclonal antibodies, any technique which provides antibodies produced by continuous cell line cultures can be used. Examples include the hybridoma technique (Kohler, G. and Milstein, C., *Nature* (1975) 256:495-497), the trioma technique, the human B-cell hybridoma technique (Kozbor *et al.*, *Immunology Today* (1983) 4:72) and the EBV-hybridoma technique (Cole *et al.*, MONOCLONAL ANTIBODIES AND CANCER THERAPY, pp. 77-96, Alan R. Liss, Inc., 1985).

[0046] Techniques for the production of single chain antibodies (U.S. Patent No. 4,946,778) can also be adapted to produce single chain antibodies to polypeptides of this invention. Also, transgenic mice, or other organisms including other mammals, may be used to express humanized antibodies.

[0047] The above-described antibodies may be employed to isolate or to identify clones expressing the polypeptide or to purify the polypeptides by affinity chromatography.

[0048] Antibodies against I κ B- β polypeptides may also be employed to treat inflammatory conditions including but not limited to rheumatoid arthritis, dermatosis (eg. psoriasis), inflammatory bowel disease, autoimmune diseases, tissue and/or organ rejection, Alzheimer's disease, stroke, atherosclerosis, restenosis, cancer, viral infection including but not limited to AIDS, osteoarthritis, osteoporosis, and Ataxia Telangiectasia, among others.

Vaccines

[0049] Another aspect of the invention relates to a method for inducing an immunological response in a mammal which comprises inoculating the mammal with $\text{I}\kappa\text{B-}\beta$ polypeptide, or a fragment thereof, adequate to produce antibody and/or T cell immune response to protect said animal from inflammatory conditions including but not limited to rheumatoid arthritis, dermatosis (eg. psoriasis), inflammatory bowel disease, autoimmune diseases, tissue and/or organ rejection, Alzheimer's disease, stroke, atherosclerosis, restenosis, cancer, viral infection including but not limited to AIDS, osteoarthritis, osteoporosis, and Ataxia Telangiectasia, among others. Yet another aspect of the invention relates to a method of inducing immunological response in a mammal which comprises, delivering $\text{I}\kappa\text{B-}\beta$ polypeptide via a vector directing expression of $\text{I}\kappa\text{B-}\beta$ polynucleotide *in vivo* in order to induce such an immunological response to produce antibody to protect said animal from diseases.

[0050] Further aspect of the invention relates to an immunological/vaccine formulation (composition) which, when introduced into a mammalian host, induces an immunological response in that mammal to a $\text{I}\kappa\text{B-}\beta$ polypeptide wherein the composition comprises a $\text{I}\kappa\text{B-}\beta$ polypeptide or $\text{I}\kappa\text{B-}\beta$ gene. The vaccine formulation may further comprise a suitable carrier. Since $\text{I}\kappa\text{B-}\beta$ polypeptide may be broken down in the stomach, it is preferably administered parenterally (including subcutaneous, intramuscular, intravenous, intradermal etc. injection). Formulations suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents or thickening agents. The formulations may be presented in unit-dose or multi-dose containers, for example, sealed ampoules and vials and may be stored in a freeze-dried condition requiring only the addition of the sterile liquid carrier immediately prior to use. The vaccine formulation may also include adjuvant systems for enhancing the immunogenicity of the formulation, such as oil-in water systems and other systems known in the art. The dosage will depend on the specific activity of the vaccine and can be readily determined by routine experimentation.

Screening Assays

[0051] The $\text{I}\kappa\text{B-}\beta$ polypeptide of the present invention may be employed in a screening process for compounds which activate (agonists) or inhibit activation of (antagonists, or otherwise called inhibitors) the $\text{I}\kappa\text{B-}\beta$ polypeptide of the present invention. Thus, polypeptides of the invention may also be used to assess identify agonist or antagonists from, for example, cells, cell-free preparations, chemical libraries, and natural product mixtures. These agonists or antagonists may be natural or modified substrates, ligands, receptors, enzymes, etc., as the case may be, of the polypeptide of the present invention; or may be structural or functional mimetics of the polypeptide of the present invention. See Coligan *et al.*, *Current Protocols in Immunology* 1(2):Chapter 5 (1991). $\text{I}\kappa\text{B-}\beta$ polypeptides are responsible for many biological functions, including many pathologies. Accordingly, it is desirable to find compounds and drugs which stimulate $\text{I}\kappa\text{B-}\beta$ polypeptide on the one hand and which can inhibit the function of $\text{I}\kappa\text{B-}\beta$ polypeptide on the other hand. In general, agonists are employed for therapeutic and prophylactic purposes for such conditions as inflammatory conditions including but not limited to rheumatoid arthritis, dermatosis (eg. psoriasis), inflammatory bowel disease, autoimmune diseases, tissue and/or organ rejection, Alzheimer's disease, stroke, atherosclerosis, restenosis, cancer, viral infection including but not limited to AIDS, osteoarthritis, osteoporosis, and Ataxia Telangiectasia. Antagonists may be employed for a variety of therapeutic and prophylactic purposes for such conditions as inflammatory conditions including but not limited to rheumatoid arthritis, dermatosis (eg. psoriasis), inflammatory bowel disease, autoimmune diseases, tissue and/or organ rejection, Alzheimer's disease, stroke, atherosclerosis, restenosis, cancer, viral infection including but not limited to AIDS, osteoarthritis, osteoporosis, and Ataxia Telangiectasia.

[0052] In general, such screening procedures may involve using appropriate cells which express the $\text{I}\kappa\text{B-}\beta$ polypeptide or respond to $\text{I}\kappa\text{B-}\beta$ polypeptide of the present invention. Such cells include cells from mammals, yeast, *Drosophila* or *E. coli*. Cells which express the $\text{I}\kappa\text{B-}\beta$ polypeptide (or cell membrane containing the expressed polypeptide) or respond to $\text{I}\kappa\text{B-}\beta$ polypeptide are then contacted with a test compound to observe binding, or stimulation or inhibition of a functional response. The ability of the cells which were contacted with the candidate compounds is compared with the same cells which were not contacted for $\text{I}\kappa\text{B-}\beta$ activity.

[0053] The assays may simply test binding of a candidate compound wherein adherence to the cells bearing the $\text{I}\kappa\text{B-}\beta$ polypeptide is detected by means of a label directly or indirectly associated with the candidate compound or in an assay involving competition with a labeled competitor. Further, these assays may test whether the candidate compound results in a signal generated by activation of the $\text{I}\kappa\text{B-}\beta$ polypeptide, using detection systems appropriate to the cells bearing the $\text{I}\kappa\text{B-}\beta$ polypeptide. Inhibitors of activation are generally assayed in the presence of a known agonist and the effect on activation by the agonist by the presence of the candidate compound is observed.

[0054] Further, the assays may simply comprise the steps of mixing a candidate compound with a solution containing a $\text{I}\kappa\text{B-}\beta$ polypeptide to form a mixture, measuring $\text{I}\kappa\text{B-}\beta$ activity in the mixture, and comparing the $\text{I}\kappa\text{B-}\beta$ activity of the

peutic amount of $\text{I}\kappa\text{B-}\beta$ polypeptides in combination with a suitable pharmaceutical carrier.

Formulation and Administration

5 [0063] Peptides, such as the soluble form of $\text{I}\kappa\text{B-}\beta$ polypeptides, and agonists and antagonist peptides or small molecules, may be formulated in combination with a suitable pharmaceutical carrier. Such formulations comprise a therapeutically effective amount of the polypeptide or compound, and a pharmaceutically acceptable carrier or excipient. Such carriers include but are not limited to, saline, buffered saline, dextrose, water, glycerol, ethanol, and combinations thereof. Formulation should suit the mode of administration, and is well within the skill of the art. The invention further
10 relates to pharmaceutical packs and kits comprising one or more containers filled with one or more of the ingredients of the aforementioned compositions of the invention.

[0064] Polypeptides and other compounds of the present invention may be employed alone or in conjunction with other compounds, such as therapeutic compounds.

[0065] Preferred forms of systemic administration of the pharmaceutical compositions include injection, typically by
15 intravenous injection. Other injection routes, such as subcutaneous, intramuscular, or intraperitoneal, can be used. Alternative means for systemic administration include transmucosal and transdermal administration using penetrants such as bile salts or fusidic acids or other detergents. In addition, if properly formulated in enteric or encapsulated formulations, oral administration may also be possible. Administration of these compounds may also be topical and/or localized, in the form of salves, pastes, gels and the like.

20 [0066] The dosage range required depends on the choice of peptide, the route of administration, the nature of the formulation, the nature of the subject's condition, and the judgment of the attending practitioner. Suitable dosages, however, are in the range of 0.1-100 $\mu\text{g/kg}$ of subject. Wide variations in the needed dosage, however, are to be expected in view of the variety of compounds available and the differing efficiencies of various routes of administration. For example, oral administration would be expected to require higher dosages than administration by intravenous injection. Variations in these dosage levels can be adjusted using standard empirical routines for optimization, as is well understood
25 in the art.

[0067] Polypeptides used in treatment can also be generated endogenously in the subject, in treatment modalities often referred to as "gene therapy" as described above. Thus, for example, cells from a subject may be engineered with a polynucleotide, such as a DNA or RNA, to encode a polypeptide *ex vivo*, and for example, by the use of a retroviral
30 plasmid vector. The cells are then introduced into the subject.

Examples

[0068] The examples below are carried out using standard techniques, which are well known and routine to those of
35 skill in the art, except where otherwise described in detail. The examples illustrate, but do not limit the invention.

Example 1

[0069] The gene expression profile of a variety of human tissues and cells, as determined by random sequencing of
40 cDNA libraries, was searched for an expressed sequence tag (EST) with homology to the murine cDNA using the FASTA algorithm of the University of Wisconsin GCG software package. This comparison yielded several gene "hits". Chain termination sequencing was carried out on the full length clone using primers selected to permit overlapping bidirectional sequencing of the entire cDNA clone.

[0070] All publications, including but not limited to patents and patent applications, cited in this specification are herein
45 incorporated by reference as if each individual publication were specifically and individually indicated to be incorporated by reference herein as though fully set forth.

50

55

mixture to a standard.

[0055] The $\text{I}\kappa\text{B-}\beta$ cDNA, protein and antibodies to the protein may also be used to configure assays for detecting the effect of added compounds on the production of $\text{I}\kappa\text{B-}\beta$ mRNA and protein in cells. For example, an ELISA may be constructed for measuring secreted or cell associated levels of $\text{I}\kappa\text{B-}\beta$ protein using monoclonal and polyclonal antibodies by standard methods known in the art, and this can be used to discover agents which may inhibit or enhance the production of $\text{I}\kappa\text{B-}\beta$ (also called antagonist or agonist, respectively) from suitably manipulated cells or tissues.

[0056] The $\text{I}\kappa\text{B-}\beta$ protein may be used to identify membrane bound or soluble receptors, if any, through standard receptor binding techniques known in the art. These include, but are not limited to, ligand binding and crosslinking assays in which the $\text{I}\kappa\text{B-}\beta$ is labeled with a radioactive isotope (eg ^{125}I), chemically modified (eg biotinylated), or fused to a peptide sequence suitable for detection or purification, and incubated with a source of the putative receptor (cells, cell membranes, cell supernatants, tissue extracts, bodily fluids). Other methods include biophysical techniques such as surface plasmon resonance and spectroscopy. In addition to being used for purification and cloning of the receptor, these binding assays can be used to identify agonists and antagonists of $\text{I}\kappa\text{B-}\beta$ which compete with the binding of $\text{I}\kappa\text{B-}\beta$ to its receptors, if any. Standard methods for conducting screening assays are well understood in the art.

[0057] Examples of potential $\text{I}\kappa\text{B-}\beta$ polypeptide antagonists include antibodies or, in some cases, oligonucleotides or proteins which are closely related to the ligands, substrates, receptors, enzymes, etc., as the case may be, of the $\text{I}\kappa\text{B-}\beta$ polypeptide, e.g., a fragment of the ligands, substrates, receptors, enzymes, etc.; or small molecules which bind to the polypeptide of the present invention but do not elicit a response, so that the activity of the polypeptide is prevented.

[0058] Thus in another aspect, the present invention relates to a screening kit for identifying agonists, antagonists, ligands, receptors, substrates, enzymes, etc. for $\text{I}\kappa\text{B-}\beta$ polypeptides; or compounds which decrease or enhance the production of $\text{I}\kappa\text{B-}\beta$ polypeptides, which comprises: (a) a $\text{I}\kappa\text{B-}\beta$ polypeptide, preferably that of SEQ ID NO:2; (b) a recombinant cell expressing a $\text{I}\kappa\text{B-}\beta$ polypeptide, preferably that of SEQ ID NO:2; (c) a cell membrane expressing a $\text{I}\kappa\text{B-}\beta$ polypeptide; preferably that of SEQ ID NO:2; or (d) antibody to a $\text{I}\kappa\text{B-}\beta$ polypeptide, preferably that of SEQ ID NO: 2. It will be appreciated that in any such kit, (a), (b), (c) or (d) may comprise a substantial component.

Prophylactic and Therapeutic Methods

[0059] This invention provides methods of treating abnormal conditions such as, inflammatory conditions including but not limited to rheumatoid arthritis, dermatosis (eg. psoriasis), inflammatory bowel disease, autoimmune diseases, tissue and/or organ rejection, Alzheimer's disease, stroke, atherosclerosis, restenosis, cancer, viral infection including but not limited to AIDS, osteoarthritis, osteoporosis, and Ataxia Telangiectasia, related to both an excess of and insufficient amounts of $\text{I}\kappa\text{B-}\beta$ polypeptide activity.

[0060] If the activity of $\text{I}\kappa\text{B-}\beta$ polypeptide is in excess, several approaches are available. One approach comprises administering to a subject an inhibitor compound (antagonist) as hereinabove described along with a pharmaceutically acceptable carrier in an amount effective to inhibit the function of the $\text{I}\kappa\text{B-}\beta$ polypeptide, such as, for example, by blocking the binding of ligands, substrates, receptors, enzymes, etc., or by inhibiting a second signal, and thereby alleviating the abnormal condition. In another approach, soluble forms of $\text{I}\kappa\text{B-}\beta$ polypeptides still capable of binding the ligand, substrate, enzymes, receptors, etc. in competition with endogenous $\text{I}\kappa\text{B-}\beta$ polypeptide may be administered. Typical embodiments of such competitors comprise fragments of the $\text{I}\kappa\text{B-}\beta$ polypeptide.

[0061] In still another approach, expression of the gene encoding endogenous $\text{I}\kappa\text{B-}\beta$ polypeptide can be inhibited using expression blocking techniques. Known such techniques involve the use of antisense sequences, either internally generated or separately administered. See, for example, O'Connor, *J Neurochem* (1991) 56:560 in Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988). Alternatively, oligonucleotides which form triple helices with the gene can be supplied. See, for example, Lee *et al.*, *Nucleic Acids Res* (1979) 6:3073; Cooney *et al.*, *Science* (1988) 241:456; Dervan *et al.*, *Science* (1991) 251:1360. These oligomers can be administered *per se* or the relevant oligomers can be expressed *in vivo*.

[0062] For treating abnormal conditions related to an under-expression of $\text{I}\kappa\text{B-}\beta$ and its activity, several approaches are also available. One approach comprises administering to a subject a therapeutically effective amount of a compound which activates $\text{I}\kappa\text{B-}\beta$ polypeptide, i.e., an agonist as described above, in combination with a pharmaceutically acceptable carrier, to thereby alleviate the abnormal condition. Alternatively, gene therapy may be employed to effect the endogenous production of $\text{I}\kappa\text{B-}\beta$ by the relevant cells in the subject. For example, a polynucleotide of the invention may be engineered for expression in a replication defective retroviral vector, as discussed above. The retroviral expression construct may then be isolated and introduced into a packaging cell transduced with a retroviral plasmid vector containing RNA encoding a polypeptide of the present invention such that the packaging cell now produces infectious viral particles containing the gene of interest. These producer cells may be administered to a subject for engineering cells *in vivo* and expression of the polypeptide *in vivo*. For overview of gene therapy, see Chapter 20, *Gene Therapy and other Molecular Genetic-based Therapeutic Approaches*, (and references cited therein) in Human Molecular Genetics, T Strachan and A P Read, BIOS Scientific Publishers Ltd (1996). Another approach is to administer a thera-

EP 0 894 855 A2

SEQUENCE LISTING

5

(1) GENERAL INFORMATION

10

(i) APPLICANT: SmithKline Beecham Corporation

(ii) TITLE OF THE INVENTION: HUMAN IkB-b

15

(iii) NUMBER OF SEQUENCES: 2

(iv) CORRESPONDENCE ADDRESS:

20

- (A) ADDRESSEE: SmithKline Beecham
Corporate Intellectual Property
- (B) STREET: Two New Horizons Court
- (C) CITY: Brentford
- (D) COUNTY: Middlesex
- (E) COUNTRY: United Kingdom
- (F) POST CODE: TW8 9EP

25

(v) COMPUTER READABLE FORM:

30

- (A) MEDIUM TYPE: Diskette
- (B) COMPUTER: IBM Compatible
- (C) OPERATING SYSTEM: DOS
- (D) SOFTWARE: FastSEQ for Windows Version 2.0

35

(vi) CURRENT APPLICATION DATA:

40

- (A) APPLICATION NUMBER: TO BE ASSIGNED
- (B) FILING DATE: 31-JUL-1997
- (C) CLASSIFICATION: UNKNOWN

(vii) PRIOR APPLICATION DATA:

45

- (A) APPLICATION NUMBER:
- (B) FILING DATE:

50

(viii) ATTORNEY/AGENT INFORMATION:

- (A) NAME: GIDDINGS, Peter John
- (B) GENERAL AUTHORISATION NUMBER: 5630
- (C) REFERENCE/DOCKET NUMBER: GH-70182

55

EP 0 894 855 A2

(ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: +44 181 975 6331

(B) TELEFAX: +44 181 975 6294

(C) TELEX:

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1227 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

CGGGTCGACC	CACGCGTCCG	CCCAGCTACA	GGCGGGCGAC	TGCGGGGGGC	CCCTGAGGCG	60
GCGGGGGCCA	TGGCTGGGGT	CGCGTGCTTG	GGAAAAGCTG	CCGACGCAGA	TGAATGGTGC	120
GACAGCGGCC	TGGGCTCCCT	GGGTCCGGAC	GCAGCGGCCC	CCGAGGAGCC	TGGGTTGGGC	180
GCGGAGTTGG	GCCCCGGGCT	GTCGTGGGCT	CCCCCTGTCT	TGGCTACGT	CACTGAGGAT	240
GGGGACACCG	CACTGCACTT	GGCTGTGATT	CATCAGCATG	AACCCTTCCT	GGATTTTCTT	300
CTAGGCTTCT	CGGCCGGCAC	TGAGTACATG	GACCTGCAGA	ATGACCTAGG	CCAGACAGCC	360
CTGCACCTGG	CAGCCATCCT	GGGGGAGACA	TCCACGGTGG	AGAAGCTGTA	CGCAGCAGGC	420
GCCGGGCTGT	GTGTGGCGGA	GCGTAGGGGC	CACACGGCGC	TGCACCTGGC	CTGCCGTGTG	480
GGGGCACACG	CCTGTGCCCG	TGCCCTGCTT	CAGCCCCGCC	CCCGGCGCCC	CAGGGAAGCC	540
CCCACACCT	ACCTCGCTCA	GGGCCCTGAC	CGTACTCCCG	ACACCAACCA	TACCCCTGTC	600
GCCTTGTAAC	CCGATTCCGA	CTTGGAAGAAG	GAAGAAGAGG	AGAGTGAGGA	GGACTGGAAG	660
CTGCAGCTGG	AGGCTGAAAA	CTACGAGGGC	CACACCCAC	TCCACGTGGC	CGTTATCCAC	720
AAAGATGTGG	AGATGGTCCG	GCTGCTCCGA	GATGCTGGAG	CTGACCTTGA	CAAACCGGAG	780
CCCACGTGCG	GCCGGAGCCC	CCTTCATTTG	GCACTGGAGG	CCCAGGCAGC	CGATGTGCTG	840
GAGCTTCTCC	TGAGGGCAGG	CGCGAACCCCT	GCTGCCCGCA	TGTACGGTGG	CCGCACCCCA	900
CTCGGCAGTG	CCATGCTCCG	GCCCAACCCC	ATCCTCGCCC	GCCTCCTCCG	TGCACACGGA	960
GCCCCTGAGC	CCGAGGGCGA	GGACGAGAAA	TCCGGCCCCCT	GCAGCAGCAG	TAGCGACAGC	1020
GACAGCGGAG	ACGAGGGCGA	TGAATACGAC	GACATTGTGG	TTCACAGCAG	CCGCAGCCAA	1080
ACCCGGCTGC	CTCCACCCCC	AGCCTCAAAA	CCTCTTCCTG	ACGACCCCCG	CCCCGTGTGA	1140
TTTGTTCAT	TGTTAATATA	ATTTCCAGTT	TAATAAACAA	AACCCTAGTT	CTGACAAACCA	1200
GGAAAAAAA	AAAAAAA	AAAAAAA				1227

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

EP 0 894 855 A2

(A) LENGTH: 357 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

```

Met Ala Gly Val Ala Cys Leu Gly Lys Ala Ala Asp Ala Asp Glu Trp
 1           5           10           15
Cys Asp Ser Gly Leu Gly Ser Leu Gly Pro Asp Ala Ala Ala Pro Gly
15           20           25           30
Gly Pro Gly Leu Gly Ala Glu Leu Gly Pro Gly Leu Ser Trp Ala Pro
 35           40           45
Leu Val Phe Gly Tyr Val Thr Glu Asp Gly Asp Thr Ala Leu His Leu
20           50           55           60
Ala Val Ile His Gln His Glu Pro Phe Leu Asp Phe Leu Leu Gly Phe
65           70           75           80
Ser Ala Gly Thr Glu Tyr Met Asp Leu Gln Asn Asp Leu Gly Gln Thr
25           85           90           95
Ala Leu His Leu Ala Ala Ile Leu Gly Glu Thr Ser Thr Val Glu Lys
 100          105          110
Leu Tyr Ala Ala Gly Ala Gly Leu Cys Val Ala Glu Arg Arg Gly His
30          115          120          125
Thr Ala Leu His Leu Ala Cys Arg Val Gly Ala His Ala Cys Ala Arg
 130          135          140
Ala Leu Leu Gln Pro Arg Pro Arg Arg Pro Arg Glu Ala Pro Asp Thr
145          150          155          160
Tyr Leu Ala Gln Gly Pro Asp Arg Thr Pro Asp Thr Asn His Thr Pro
 165          170          175
Val Ala Leu Tyr Pro Asp Ser Asp Leu Glu Lys Glu Glu Glu Glu Ser
40          180          185          190
Glu Glu Asp Trp Lys Leu Gln Leu Glu Ala Glu Asn Tyr Glu Gly His
 195          200          205
Thr Pro Leu His Val Ala Val Ile His Lys Asp Val Glu Met Val Arg
210          215          220
Leu Leu Arg Asp Ala Gly Ala Asp Leu Asp Lys Pro Glu Pro Thr Cys
45          225          230          235          240
Gly Arg Ser Pro Leu His Leu Ala Val Glu Ala Gln Ala Ala Asp Val
 245          250          255
Leu Glu Leu Leu Leu Arg Ala Gly Ala Asn Pro Ala Ala Arg Met Tyr
50          260          265          270
Gly Gly Arg Thr Pro Leu Gly Ser Ala Met Leu Arg Pro Asn Pro Ile

```

275 280 285
 5 Leu Ala Arg Leu Leu Arg Ala His Gly Ala Pro Glu Pro Glu Gly Glu
 290 295 300
 Asp Glu Lys Ser Gly Pro Cys Ser Ser Ser Ser Asp Ser Asp Ser Gly
 305 310 315 320
 10 Asp Glu Gly Asp Glu Tyr Asp Asp Ile Val Val His Ser Ser Arg Ser
 325 330 335
 Gln Thr Arg Leu Pro Pro Thr Pro Ala Ser Lys Pro Leu Pro Asp Asp
 340 345 350
 15 Pro Arg Pro Val
 355

Claims

1. An isolated polynucleotide comprising a nucleotide sequence that has at least 90% identity over its entire length to a nucleotide sequence encoding the I κ B- β polypeptide of SEQ ID NO:2; or a nucleotide sequence complementary to said isolated polynucleotide.
2. The polynucleotide of claim 1 wherein said polynucleotide comprises the nucleotide sequence contained in SEQ ID NO:1 encoding the I κ B- β polypeptide of SEQ ID NO:2.
3. The polynucleotide of claim 1 wherein said polynucleotide comprises a nucleotide sequence that is at least 90% identical to that of SEQ ID NO: 1 over its entire length.
4. The polynucleotide of claim 3 which is polynucleotide of SEQ ID NO: 1.
5. The polynucleotide of claim 1 which is DNA or RNA.
6. A DNA or RNA molecule comprising an expression system, wherein said expression system is capable of producing a I κ B- β polypeptide comprising an amino acid sequence, which has at least 97% identity with the polypeptide of SEQ ID NO:2 when said expression system is present in a compatible host cell.
7. A host cell comprising the expression system of claim 6.
8. A process for producing a I κ B- β polypeptide comprising culturing a host of claim 7 under conditions sufficient for the production of said polypeptide and recovering the polypeptide from the culture.
9. A process for producing a cell which produces a I κ B- β polypeptide thereof comprising transforming or transfecting a host cell with the expression system of claim 6 such that the host cell, under appropriate culture conditions, produces a I κ B- β polypeptide.
10. A I κ B- β polypeptide comprising an amino acid sequence which is at least 97% identical to the amino acid sequence of SEQ ID NO:2 over its entire length.
11. The polypeptide of claim 10 which comprises the amino acid sequence of SEQ ID NO:2.
12. An antibody immunospecific for the I κ B- β polypeptide of claim 10.
13. A method for the treatment of a subject in need of enhanced activity or expression of I κ B- β polypeptide of claim 10 comprising:

(a) administering to the subject a therapeutically effective amount of an agonist to said polypeptide; and/or
(b) providing to the subject an isolated polynucleotide comprising a nucleotide sequence that has at least 90% identity to a nucleotide sequence encoding the I κ B- β polypeptide of SEQ ID NO:2 over its entire length; or a nucleotide sequence complementary to said nucleotide sequence in a form so as to effect production of said polypeptide activity *in vivo*.

14. A method for the treatment of a subject having need to inhibit activity or expression of I κ B- β polypeptide of claim 10 comprising:

(a) administering to the subject a therapeutically effective amount of an antagonist to said polypeptide; and/or
(b) administering to the subject a nucleic acid molecule that inhibits the expression of the nucleotide sequence encoding said polypeptide; and/or
(c) administering to the subject a therapeutically effective amount of a polypeptide that competes with said polypeptide for its ligand, substrate or receptor.

15. A process for diagnosing a disease or a susceptibility to a disease in a subject related to expression or activity of I κ B- β polypeptide of claim 10 in a subject comprising:

(a) determining the presence or absence of a mutation in the nucleotide sequence encoding said I κ B- β polypeptide in the genome of said subject; and/or
(b) analyzing for the presence or amount of the I κ B- β polypeptide expression in a sample derived from said subject.

16. A method for identifying compounds which inhibit (antagonize) or agonize the I κ B- β polypeptide of claim 10 which comprises:

(a) contacting a candidate compound with cells which express the I κ B- β polypeptide (or cell membrane expressing I κ B- β polypeptide) or respond to I κ B- β polypeptide; and
(b) observing the binding, or stimulation or inhibition of a functional response; or comparing the ability of the cells (or cell membrane) which were contacted with the candidate compounds with the same cells which were not contacted for I κ B- β polypeptide activity.

17. An agonist identified by the method of claim 16.

18. An antagonist identified by the method of claim 16.

19. A recombinant host cell produced by a method of Claim 9 or a membrane thereof expressing a I κ B- β polypeptide.

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 0 894 855 A3

(12)

EUROPEAN PATENT APPLICATION

(88) Date of publication A3:
22.12.1999 Bulletin 1999/51

(51) Int. Cl.⁶: **C12N 15/12**, C07K 14/47,
C12N 5/10, C07K 16/18,
G01N 33/53, G01N 33/68

(43) Date of publication A2:
03.02.1999 Bulletin 1999/05

(21) Application number: **97310566.1**

(22) Date of filing: **23.12.1997**

(84) Designated Contracting States:
**AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC
NL PT SE**
Designated Extension States:
AL LT LV MK RO SI

(30) Priority: **31.07.1997 US 903851**

(71) Applicant:
SMITHKLINE BEECHAM CORPORATION
Philadelphia Pennsylvania 19103 (US)

(72) Inventor:
Chabot-Fletcher, Marie C.,
SmithKline Beecham Pha.
King of Prussia, Pennsylvania 19406 (US)

(74) Representative:
Crump, Julian Richard John et al
FJ Cleveland,
40-43 Chancery Lane
London WC2A 1JQ (GB)

(54) **Human I kappa B-beta transcription factor**

(57) I κ B- β polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing I κ B- β polypeptides and polynucleotides in the design of protocols for the treatment of inflammatory conditions including but not limited to rheumatoid arthritis, dermatosis (eg. psoriasis), inflammatory bowel disease, autoimmune diseases, tissue and/or organ rejection, Alzheimer's disease, stroke, atherosclerosis, restenosis, cancer, viral infection including but not limited to AIDS, osteoarthritis, osteoporosis, and Ataxia Telangiectasia, among others, and diagnostic assays for such conditions.

EP 0 894 855 A3



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number

which under Rule 45 of the European Patent Convention shall be considered, for the purposes of subsequent proceedings, as the European search report

EP 97 31 0566

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.6)
X	LEE J W ET AL: "TWO CLASSES OF PROTEINS DEPENDENT ON EITHER THE PRESENCE OR ABSENCE OF THYROID HORMONE FOR INTERACTION WITH THE THYROID HORMONE RECEPTOR" MOLECULAR ENDOCRINOLOGY, vol. 9, no. 2, 1 February 1995 (1995-02-01), pages 243-254, XP002055584 ISSN: 0888-8809 * the whole document *	6-9	C12N15/12 C07K14/47 C12N5/10 C07K16/18 G01N33/53 G01N33/68
X	THOMPSON, J.E. ET AL.: "IkappaB-beta regulates the persistent response in a biphasic activation of NF-kappaB" CELL, vol. 80, 1995, pages 573-82, XP002119162 see the whole document, particularly fig. 5 and 6. --- -/--	12,18	
			TECHNICAL FIELDS SEARCHED (Int.Cl.6)
			C12N C07K G01N
INCOMPLETE SEARCH			
<p>The Search Division considers that the present application, or one or more of its claims, does/do not comply with the EPC to such an extent that a meaningful search into the state of the art cannot be carried out, or can only be carried out partially, for these claims.</p> <p>Claims searched completely :</p> <p>Claims searched incompletely :</p> <p>Claims not searched :</p> <p>Reason for the limitation of the search:</p> <p>see sheet C</p>			
Place of search THE HAGUE		Date of completion of the search 18 October 1999	Examiner Smalt, R
<p>CATEGORY OF CITED DOCUMENTS</p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons S : member of the same patent family, corresponding document</p>			

EPO FORM 1503 03.82 (P&C07)



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number
EP 97 31 0566

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
Y	<p>DATABASE EMBL - EMBEST25 'Online! Entry HSAA61798, Acc.no. AA261798, 20 March 1997 (1997-03-20) STRAUSBERG, R.: "zs16f05.r1 NCI_CGAP_GCB1 Homo sapiens cDNA clone IMAGE:685377 5' similar to TR:G699497 G699497 IKB-BETA." XP002119163 * the whole document *</p>	1-13, 15-17,19	
Y	<p>DATABASE EMBL - EMBEST20 'Online! Entry HS1238126, Acc.no. AA436841, 1 June 1997 (1997-06-01) HILLIER, L. ET AL.: "zv57g12.s1 Soares testis NHT Homo sapiens cDNA clone 757798 3' similar to TR:G699497 G699497 IKB-BETA." XP002119164 * the whole document *</p>	1-13, 15-17,19	TECHNICAL FIELDS SEARCHED
Y	<p>WO 92 20795 A (CETUS ONCOLOGY CORP ;UNIV NORTH CAROLINA (US)) 26 November 1992 (1992-11-26) see whole document, particularly the claims.</p>	1-13, 15-17,19	

EPO FORM 1503 03.82 (P04C10)



European Patent
Office

INCOMPLETE SEARCH
SHEET C

Application Number
EP 97 31 0566

Although claims 13 and 14 are directed to a method of treatment of the human/animal body (Article 52(4) EPC), the search has been carried out and based on the alleged effects of the compound/composition.

Claim(s) searched incompletely:
13,14,17,18

Reason for the limitation of the search:

Claims 13,14,17, and 18 could not be searched to completion due to insufficient characterization in the description of the (ant)agonists, expression inhibiting nucleic acid molecules, and/or competing peptides.

ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.

EP 97 31 0566

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

18-10-1999

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9220795 A	26-11-1992	AU 2140592 A	30-12-1992
		AU 709603 B	02-09-1999
		AU 7062196 A	06-02-1997
		CA 2102704 A	18-11-1992
		EP 0584238 A	02-03-1994
		JP 6508029 T	14-09-1994
		US 5830756 A	03-11-1998
		US 5846714 A	08-12-1998

EPO FORM P459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

THIS PAGE BLANK (USPTO)